Everything You Need to Know About the Zantac Lawsuit

Spread the love

You probably remember seeing Zantac on the shelves in your pharmacy, or commercials for the prescription-strength heartburn reliever. However, Zantac was recalled by the FDA in April 2020 due to concerns over the purity of the active ingredient ranitidine. Following this recall, past users of the product are now looking into legal action to benefit themselves and their family members because of an onset of medical expenses and other issues that arose from simply trying to aid acid reflux and indigestion.

The Problem with Zantac

Scientific evidence determined that Zantac contained high levels of NDMA, a probable human carcinogen that is not high risk at low levels. However, those levels increased in the bloodstream with the long-term use of Zantac. This led to the development of new systems, with cancer research finding that this resulted in the development of health problems related to pancreatic cancer, stomach cancer, brain cancer, and other ailments.

This has led law firms to form a class-action Zantac lawsuit to allow for fair compensation for those who were impacted by the presence of NDMA, leading to greater cancer risk. This personal injury lawsuit was designed for those who had taken Zantac but did not receive a cancer diagnosis. Many individual Zantac cancer lawsuits are being consolidated into multidistrict litigation filed against Zantac manufacturer Sanofi in the Southern District of Florida. The Zantac CAL has been consolidated in the Southern District of Florida.

Who qualifies for this lawsuit?

Through a lawyer referral service, you may learn more about the legal action being taken regarding prescription and over-the-counter Zantac. Free consultation regarding this lawsuit does not require you to sign up for this legal action against pharmaceutical company Sanofi and the manufacturers of ranitidine. If you do not qualify for a Zantac cancer lawsuit, you may still qualify for a Zantac class-action lawsuit if you took Zantac and were unaware of the cancer risks associated with the drug. These should align with the timing of the Zantac recall, and applicants should demonstrate those high levels of carcinogenic substances.

While pancreatitis, stomach cancer, and brain cancer have been among the common forms of cancer tied to those high levels of NDMA in Zantac, these lawsuits have expanded the net to cover other forms of cancer. Beyond cancer, other personal injury litigation has sprouted up in law firms across the U.S. to provide greater safety in public health. These lawsuits address the numerous recalls in relation to other illnesses and conditions such as primary pulmonary hypertension, better known as high blood pressure in the lungs. Crohn’s disease has also popped up in recent class-action lawsuits.

How much can you earn in compensation?

The anticipated compensation from a Zantac lawsuit for any applying patient would include the total economic damages that you have already incurred, as well as future economic damages, and non-economic damages. This includes pain and suffering, and other related damages. Based on current Zantac settlement amounts, plaintiffs can expect to receive between $20,000 to $400,000 in compensation depending on the severity of the case. This can help cover outstanding expenses with healthcare providers, as well as any loss of income resulting from being off the job.

Plaintiffs accuse drugmakers Sanofi and Boehringer Ingelheim of manufacturing and marketing a medication they knew, or should have known, to be contaminated with NDMA without disclosing the risks to consumers or the government. This has also left those suffering from gastrointestinal problems scrambling for another solution to treat their symptoms. Settlements from Zantac manufacturers can help patients to pay the medical bills that have resulted from not only treatment of ailments, but from still trying to take care of the initial gastro issue that had been plaguing them.

Leave a Reply

Your email address will not be published. Required fields are marked *